Teva Pharma (TEVA) Tops Q3 EPS by 2c; Offers Q4 Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. ARM
3. FIS
4. BROS
5. EXPE
6. QCOM
7. CPAY
8. PAYC
9. EW
10. RPD

Go back to Teva Pharma (TEVA) Tops Q3 EPS by 2c; Offers Q4 Outlook

2017 Seen as a Challenge for Teva (TEVA), But Sticking with 'Buy' - Maxim

November 16, 2016 8:25 AM EST

Maxim Group analyst Gabrielle Zhou lowered her price target on Teva Pharma (NYSE: TEVA) to $52.00 (from $72.00) but maintained a Buy rating following results. The firm sees 2017 as a challenge.

Zhou commented:

Teva reported 3Q16 with total revenues of $5.6B, with $2.9B in generic product revenues, including $887M from the Actavis generic business (transaction completed on Aug. 2, 2016). Total generic revenues increased 26% sequentially, compared to $2.3B in 2Q16. Specialty revenues were $2B, down 10%... More

Jefferies Downgrades Teva Pharma (TEVA) to Hold; Too Many Headwinds

November 16, 2016 6:32 AM EST

Jefferies downgraded Teva Pharma (NYSE: TEVA) from Buy to Hold with a price target of $40.00 (from $69.00), saying there are too many headwinds.

Analyst David Steinberg commented, "Our view has changed. We now think there is little over the next year... More

Teva Pharma (TEVA): Concerns on Generics Overdone - Guggenheim

November 15, 2016 10:26 AM EST

Guggenheim analyst Louise Chen reiterated a Buy rating and $80 price target on Teva Pharma (NYSE: TEVA) following results. The analyst said concerns that generic sales are disappearing are overdone.

Chen commented, "TEVA reported a 3Q16 beat, underscoring our belief that its execution is still... More